VivoSeq
Oncology

High-Risk Neuroblastoma

8

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

High-Risk Neuroblastoma is an early-stage landscape with 8 programs across 6 companies. The most active players are Gilead, BeiGene, Iovance Biotherapeutics, Inc.. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 3United Therapeutics logo

United Therapeutics

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3R

Renaissance Pharma Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

6programs
Monoclonal antibody350%
Protein / enzyme233%
Small molecule117%

Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

4

clinical trials

Not yet recruiting1 · 25%
Recruiting1 · 25%
Terminated1 · 25%
Completed1 · 25%

Clinical Trials

Trial Activity

Pilot Study of Combining of Dinutuximab-β With Induction Chemotherapy in Newly Diagnosed High Risk Neuroblastoma
Not yet recruiting·CChang Gung Memorial Hospital·Phase 1·NCT07688252·30 enrolled
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination With Chemotherapy in Participants With High-Risk Neuroblastoma
Recruiting·RRenaissance Pharma Ltd.·Preclinical·NCT07549321·144 enrolled
Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma
Terminated·National Cancer Institute (NCI)·Phase 1·NCT04751383·12 enrolled
A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy
Completed·National Cancer Institute (NCI)·Phase 3·NCT01041638·105 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)